UNLABELLED: The synthesis and validation of a new, highly potent (64)Cu-labeled peptide, cFLFLFK-PEG-(64)Cu, that targets the formyl peptide receptor (FPR) on leukocytes is described. The peptide ligand is an antagonist of the FPR, designed not to elicit a chemotactic response resulting in neutropenia. Evidence for the selective binding of this synthesized ligand to neutrophils is provided. PET properties of the compound were evaluated in a mouse model of lung inflammation. METHODS: The FPR-specific peptide, cinnamoyl-F-(D)L-F-(D)L-FK (cFLFLF), was sequentially conjugated with a bifunctional polyethylene glycol moiety (PEG, 3.4 kD) and a 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid (DOTA) through a lysine (K) spacer and finally labeled with (64)Cu-CuCl(2) to form cFLFLFK-PEG-(64)Cu. The binding affinity and stimulation potency of the ligand toward human neutrophils were assessed in vitro. Blood kinetic and organ biodistribution properties of the peptide were studied in the mouse. Ten male C57BL/6 mice were used in this study; 4 control mice and 6 administered Klebsiella pneumonia. PET/CT scans were performed to assess the localization properties of the labeled peptide in lungs 18 h after tracer administration. Lung standardized uptake values (SUVs) were correlated with lung neutrophil activity as measured by myeloperoxidase assays. Immunohistochemistry was performed to confirm that neutrophils constitute the majority of infiltrating leukocytes in lung tissue 24 h after Klebsiella exposure. RESULTS: In vitro binding assays of the compound cFLFLFK-PEG-(64)Cu to the neutrophil FPR yielded a dissociation constant of 17.7 nM. The functional superoxide stimulation assay exhibited negligible agonist activity of the ligand with respect to neutrophil superoxide production. The pegylated peptide ligand exhibited a blood clearance half-life of 55 +/- 8 min. PET 18 h after tracer administration revealed mean lung SUVs and lung myeloperoxidase activities for Klebsiella-infected mice that were 5- and 6-fold higher, respectively, than those for control mice. Immunohistochemistry staining confirmed that the cellular infiltrate in lungs of Klebsiella-infected mice was almost exclusively neutrophils at the time of imaging. CONCLUSION: This new radiolabeled peptide targeting the FPR binds to neutrophils in vitro and accumulates at sites of inflammation in vivo. This modified peptide may prove to be a useful tool to probe inflammation or injury.
UNLABELLED: The synthesis and validation of a new, highly potent (64)Cu-labeled peptide, cFLFLFK-PEG-(64)Cu, that targets the formyl peptide receptor (FPR) on leukocytes is described. The peptide ligand is an antagonist of the FPR, designed not to elicit a chemotactic response resulting in neutropenia. Evidence for the selective binding of this synthesized ligand to neutrophils is provided. PET properties of the compound were evaluated in a mouse model of lung inflammation. METHODS: The FPR-specific peptide, cinnamoyl-F-(D)L-F-(D)L-FK (cFLFLF), was sequentially conjugated with a bifunctional polyethylene glycol moiety (PEG, 3.4 kD) and a 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid (DOTA) through a lysine (K) spacer and finally labeled with (64)Cu-CuCl(2) to form cFLFLFK-PEG-(64)Cu. The binding affinity and stimulation potency of the ligand toward human neutrophils were assessed in vitro. Blood kinetic and organ biodistribution properties of the peptide were studied in the mouse. Ten male C57BL/6 mice were used in this study; 4 control mice and 6 administered Klebsiella pneumonia. PET/CT scans were performed to assess the localization properties of the labeled peptide in lungs 18 h after tracer administration. Lung standardized uptake values (SUVs) were correlated with lung neutrophil activity as measured by myeloperoxidase assays. Immunohistochemistry was performed to confirm that neutrophils constitute the majority of infiltrating leukocytes in lung tissue 24 h after Klebsiella exposure. RESULTS: In vitro binding assays of the compound cFLFLFK-PEG-(64)Cu to the neutrophil FPR yielded a dissociation constant of 17.7 nM. The functional superoxide stimulation assay exhibited negligible agonist activity of the ligand with respect to neutrophil superoxide production. The pegylated peptide ligand exhibited a blood clearance half-life of 55 +/- 8 min. PET 18 h after tracer administration revealed mean lung SUVs and lung myeloperoxidase activities for Klebsiella-infectedmice that were 5- and 6-fold higher, respectively, than those for control mice. Immunohistochemistry staining confirmed that the cellular infiltrate in lungs of Klebsiella-infectedmice was almost exclusively neutrophils at the time of imaging. CONCLUSION: This new radiolabeled peptide targeting the FPR binds to neutrophils in vitro and accumulates at sites of inflammation in vivo. This modified peptide may prove to be a useful tool to probe inflammation or injury.
Authors: A J Fischman; M C Pike; D Kroon; A J Fucello; D Rexinger; C ten Kate; R Wilkinson; R H Rubin; H W Strauss Journal: J Nucl Med Date: 1991-03 Impact factor: 10.057
Authors: Zhaohui Zhou; James Kozlowski; Andrea L Goodrich; Nathaniel Markman; Delphine L Chen; Daniel P Schuster Journal: Am J Physiol Lung Cell Mol Physiol Date: 2005-06-24 Impact factor: 5.464
Authors: Yi Zhang; Bijoy Kundu; Karen D Fairchild; Landon Locke; Stuart S Berr; Joel Linden; Dongfeng Pan Journal: Bioorg Med Chem Lett Date: 2007-10-12 Impact factor: 2.823
Authors: Xiaoyuan Chen; Yingping Hou; Michel Tohme; Ryan Park; Vazgen Khankaldyyan; Ignacio Gonzales-Gomez; James R Bading; Walter E Laug; Peter S Conti Journal: J Nucl Med Date: 2004-10 Impact factor: 10.057
Authors: Evgenyi B Eruslanov; Irina V Lyadova; Tatiana K Kondratieva; Konstantin B Majorov; Ilya V Scheglov; Marianna O Orlova; Alexander S Apt Journal: Infect Immun Date: 2005-03 Impact factor: 3.441
Authors: Tamara Boltersdorf; Junaid Ansari; Elena Y Senchenkova; Jieny Groeper; Denise Pajonczyk; Shantel A Vital; Gaganpreet Kaur; J Steve Alexander; Thomas Vogl; Ursula Rescher; Nicholas J Long; Felicity N E Gavins Journal: Theranostics Date: 2020-05-17 Impact factor: 11.556
Authors: Rhett N Willis; Eric J Charles; Christopher A Guidry; Mahendra D Chordia; Stephen W Davies; Zequan Yang; Robert G Sawyer Journal: J Surg Res Date: 2017-04-07 Impact factor: 2.192
Authors: Li Xiao; Tinghui Li; Mengmeng Ding; Jiezuan Yang; José Rodríguez-Corrales; Stephen M LaConte; Nicholas Nacey; David B Weiss; Li Jin; Harry C Dorn; Xudong Li Journal: Bioconjug Chem Date: 2017-02-06 Impact factor: 4.774
Authors: Edwin R Manuel; Jeremy Chen; Massimo D'Apuzzo; Melanie G Lampa; Teodora I Kaltcheva; Curtis B Thompson; Thomas Ludwig; Vincent Chung; Don J Diamond Journal: Cancer Immunol Res Date: 2015-07-01 Impact factor: 11.151
Authors: Eric J Charles; Mahendra D Chordia; Yunge Zhao; Yi Zhang; J Hunter Mehaffey; David K Glover; Julien Dimastromatteo; W Zachary Chancellor; Ashish K Sharma; Irving L Kron; Dongfeng Pan; Victor E Laubach Journal: Am J Physiol Lung Cell Mol Physiol Date: 2019-12-04 Impact factor: 5.464
Authors: Li Xiao; Yi Zhang; Wei Yue; Xiuzhen Xie; Ji-Ping Wang; Mahendra D Chordia; Leland W K Chung; Dongfeng Pan Journal: Nucl Med Biol Date: 2013-02-01 Impact factor: 2.408